CardioRenal Systems, Inc.

CardioRenal Systems develops the RenalPro (RenalGuard outside the US) autonomously-controlled fluid management and therapeutic system designed to prevent acute kidney injury (AKI) across multiple clinical settings. RenalPro is an FDA-designated breakthrough device that responds to minute fluctuations in urine output while automatically adjusting IV fluid administration in 1 mL increments to maintain hemodynamic stability and prevent over- or under-hydration. The company's primary focus is cardiac surgery-associated AKI (CSA-AKI), where approximately 30% of patients suffer kidney injury post-operatively. In a randomized 220-patient UK study, RenalPro demonstrated a 52% reduction in AKI compared to standard care with no reported adverse events. The system also addresses contrast-associated AKI (CA-AKI) in catheterization lab procedures and shows potential for ICU-related AKI prevention in septic and critically ill patients. RenalPro integrates into existing clinical workflows and represents an alternative to traditional KDIGO bundle protocols, which demonstrate limited efficacy. The company holds ISO 13485 certification and FDA breakthrough device designation, positioning it as a specialized solution for kidney injury prevention in surgical and interventional cardiology settings.